Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer

About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known.

Trial Details

NCT ID
NCT06292286
Phase
NA
Sponsor
The University of Hong Kong
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Carboplatin or cisplatin
  • Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar
  • Bevacizumab or biosimilar
  • Cytoreductive surgery
Locations (sample)
  • Hong Kong, Hong Kong|22.27832,114.17469

Key Eligibility Criteria

  • Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma
  • \>= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and / or PARPi, at primary setting
  • Platinum-free interval should be \>=6 months from the last dose of platinum-based chemotherapy
  • Upfront SCR not feasible

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →